<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846128</url>
  </required_header>
  <id_info>
    <org_study_id>2017/181/HP</org_study_id>
    <nct_id>NCT03846128</nct_id>
  </id_info>
  <brief_title>Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer</brief_title>
  <acronym>BIOSUNTOX</acronym>
  <official_title>Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney
      cancer.

      Collection of additional blood tubes during routine blood tests for patient follow-up, to
      evaluate the plasma concentration of Sunitinib and its active metabolite desethyl-Sunitinib
      (DES)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</measure>
    <time_frame>At the end of Cycle 3 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</measure>
    <time_frame>At the end of Cycle 4 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</measure>
    <time_frame>At the end of Cycle 5 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</measure>
    <time_frame>At the end of Cycle 3 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</measure>
    <time_frame>At the end of Cycle 4 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</measure>
    <time_frame>At the end of Cycle 5 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 28 days)</time_frame>
    <description>hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma desethyl-Sunitinib (DES) concentration</measure>
    <time_frame>Cycle1 Day14 (each cycle is 28 days)</time_frame>
    <description>influence of plasma DES concentration on patients survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma Sunitinib concentration</measure>
    <time_frame>Cycle1 Day14 (each cycle is 28 days)</time_frame>
    <description>influence of plasma Sunitinib concentration on patients survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma Sunitinib concentration</measure>
    <time_frame>Cycle1 Day28 (each cycle is 28 days)</time_frame>
    <description>influence of plasma Sunitinib concentration on patients survivall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma DES concentration</measure>
    <time_frame>Cycle1 Day28 (each cycle is 28 days)</time_frame>
    <description>influence of plasma Sunitinib concentration on patients survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma Sunitinib concentration</measure>
    <time_frame>Cycle2 Day28(each cycle is 28 days)</time_frame>
    <description>influence of plasma Sunitinib concentration on patients survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma DES concentration</measure>
    <time_frame>Cycle2 Day28 (each cycle is 28 days)</time_frame>
    <description>influence of plasma DES concentration on patients survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma Sunitinib concentration</measure>
    <time_frame>Cycle3 Day28 (each cycle is 28 days)</time_frame>
    <description>influence of plasma Sunitinib concentration on patients survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma DES concentration</measure>
    <time_frame>Cycle3 Day28 (each cycle is 28 days)</time_frame>
    <description>Evaluate the influence of plasma DES concentration on patients survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma Sunitinib concentration</measure>
    <time_frame>Cycle6 Day28 (each cycle is 28 days)</time_frame>
    <description>influence of plasma Sunitinib concentration on patients survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma DES concentration</measure>
    <time_frame>Cycle6 Day28 (each cycle is 28 days)</time_frame>
    <description>influence of plasma DES concentration on patients survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Metastatic Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney
        cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient at least 18 years old

          -  Patient who read and understood the newsletter and signed the consent form

          -  Renal cell carcinoma histologically proven stage IV

          -  Metastatic stage proven on CT, synchronous or metachronous examination

          -  Patient operated on or not from the primary tumor

          -  Eligible for first-line systemic therapy with Sunitinib-targeted therapy for oncology
             urology

          -  Affiliation to a social security scheme

          -  Effective contraception (as defined by the WHO) for at least 3 months at the inclusion
             visit, during treatment and for 1 month after the end of the research (negative
             pregnancy test)

          -  Postmenopausal woman: confirmatory diagnosis (amenorrhea not clinically induced for
             more than 12 months at inclusion visit)

          -  General condition WHO 0 to 2

          -  Life expectancy estimated at more than 6 months at baseline

        Exclusion Criteria:

          -  Non-metastatic disease

          -  Other cancer proven histologically, or in complete remission for less than 2 years

          -  Contraindication to SUTENT 50 mg hard capsules: Hypersensitivity to the active
             substance or to any of the excipients

          -  History of immunotherapy treatment for kidney cancer, previous treatment with targeted
             therapies for the same or previous cancer

          -  Pregnant or lactating woman or wishing to breastfeed within 6 months after the last
             treatment or no known contraception,

          -  Person deprived of liberty by an administrative or judicial decision or person placed
             under the protection of justice / sub-guardianship or curatorship

          -  Patient currently involved in an interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

